ArticleRomanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
Biology of recurrent cholesteatoma in a Romanian young patient - a case report.
Article in Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Quality of Life Outcomes After Endoscopic Cholesteatoma Surgery: A Prospective Cohort Study.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cholesteatoma is an otologic pathology that can occur at any age and can lead to a variety of complications including facial palsy, intracranial abscess, hearing loss, venous thrombosis. Cholesteatoma, even if considered a benign condition, associates high risks of recurrency due to its invasiveness. We describe a case of recurrent cholesteatoma in a young boy who presented chronic ear discharge and hearing loss for which had undergone three surgical interventions between the ages of 16 and 19 years old, from 2019 to 2022. Pediatric cholesteatoma is more prone to recurrency. Considering surgical excision as the only treatment at the current moment, it is highly important to understand the biology of cholesteatoma lesional extension for further treatment management improvement. Good research of angiogenesis, chronic inflammation and immune infiltration correlated with surgical approach may be the future for preventing cholesteatoma recurrency.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.